Check our MATCH-R collection
Special PDX models established from patients who proved demonstrated acquired resistance to last generation therapies !
Drive your future research now by clicking below !
Premium preclinical CRO offering innovative solutions for the development of new anticancer therapies
As a preclinical oncology CRO, XenTech believe in expertise, carry innovative values and creative solutions to facilitate and make emerge new efficient tools to fight cancer globally. We’re not in the size or numbers’ race but rather favor precisely targeted tools and services that will provide easier and faster solutions to the oncology research community and ultimately improve patients’ health.
With this spirit we are constantly evolving and prefer focusing on underserved niche (pediatric oncology), accurate models addressing nowadays needs in oncology research (MATCH-R line of PDX reflecting acquired resistance to newly approved or in clinical evaluation drugs) and capitalize on our historic expertise in Breast cancer for which we aim to be THE #1 Reference.Discover
XenTech exhibits at EACR 2022 (Seville, Jun. 20-23 2022)Discover
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants
CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.
XenTech exhibits at AACR Annual Meeting (New Orleans, Apr.8-13 2022)
We'll be exhibiting at AACR New Orleans from Apr.8th 2022, stop by our booth to chat with us (at last!)